DPP4 and metabolic dysfunction-associated steatotic liver disease: DPP-4 inhibitors may be able to attenuate the pathology of NASH, because patients with NAFLD/NASH have increased DPP-4 activity, which correlates with the histological severity of NASH [20,21,22].